Cargando…

Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD

INTRODUCTION: We examined the impact of autoantibodies on the erythropoietin receptor (EPOR) in type 2 diabetic patients with chronic kidney disease (CKD). METHODS: A total of 112 Japanese patients with type 2 diabetes who had CKD were enrolled in this study and followed for a mean of 45 months. Ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, Akinori, Furuichi, Kengo, Koshino, Akihiko, Yasuda, Haruka, Tran, Trang Thi Thu, Iwata, Yasunori, Sakai, Norihiko, Shimizu, Miho, Kaneko, Shuichi, Nakamura, Hiroyuki, Wada, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762966/
https://www.ncbi.nlm.nih.gov/pubmed/29340323
http://dx.doi.org/10.1016/j.ekir.2017.08.017
_version_ 1783291801467092992
author Hara, Akinori
Furuichi, Kengo
Koshino, Akihiko
Yasuda, Haruka
Tran, Trang Thi Thu
Iwata, Yasunori
Sakai, Norihiko
Shimizu, Miho
Kaneko, Shuichi
Nakamura, Hiroyuki
Wada, Takashi
author_facet Hara, Akinori
Furuichi, Kengo
Koshino, Akihiko
Yasuda, Haruka
Tran, Trang Thi Thu
Iwata, Yasunori
Sakai, Norihiko
Shimizu, Miho
Kaneko, Shuichi
Nakamura, Hiroyuki
Wada, Takashi
author_sort Hara, Akinori
collection PubMed
description INTRODUCTION: We examined the impact of autoantibodies on the erythropoietin receptor (EPOR) in type 2 diabetic patients with chronic kidney disease (CKD). METHODS: A total of 112 Japanese patients with type 2 diabetes who had CKD were enrolled in this study and followed for a mean of 45 months. Sera from these patients were screened for anti-EPOR antibodies using enzyme-linked immunosorbent assays. RESULTS: Anti-EPOR antibodies were detected in 26 patients (23%). Anti-EPOR antibodies were associated with low hemoglobin concentrations and decreased renal function. In patients with biopsy-proven diabetic nephropathy, anti-EPOR antibodies were associated with increased levels of interstitial inflammation. A decrease in renal function was observed more frequently in patients with antibodies than in those without antibodies, and the presence of the antibodies together with well-known clinical parameters, including proteinuria and low glomerular filtration rate, was a significant risk factor for end-stage renal disease. In human tubular epithelial HK-2 cells, IgG fractions containing anti-EPOR antibodies upregulated the expression of monocyte chemoattractant protein-1 mRNA under a high concentration of glucose. CONCLUSION: Anti-EPOR antibodies might be involved in the progression of renal lesions and in the impaired erythropoiesis in type 2 diabetic patients with CKD. Furthermore, the presence of anti-EPOR antibodies may be an additional predictor for end-stage renal disease in type 2 diabetes.
format Online
Article
Text
id pubmed-5762966
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-57629662018-01-16 Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD Hara, Akinori Furuichi, Kengo Koshino, Akihiko Yasuda, Haruka Tran, Trang Thi Thu Iwata, Yasunori Sakai, Norihiko Shimizu, Miho Kaneko, Shuichi Nakamura, Hiroyuki Wada, Takashi Kidney Int Rep Clinical Research INTRODUCTION: We examined the impact of autoantibodies on the erythropoietin receptor (EPOR) in type 2 diabetic patients with chronic kidney disease (CKD). METHODS: A total of 112 Japanese patients with type 2 diabetes who had CKD were enrolled in this study and followed for a mean of 45 months. Sera from these patients were screened for anti-EPOR antibodies using enzyme-linked immunosorbent assays. RESULTS: Anti-EPOR antibodies were detected in 26 patients (23%). Anti-EPOR antibodies were associated with low hemoglobin concentrations and decreased renal function. In patients with biopsy-proven diabetic nephropathy, anti-EPOR antibodies were associated with increased levels of interstitial inflammation. A decrease in renal function was observed more frequently in patients with antibodies than in those without antibodies, and the presence of the antibodies together with well-known clinical parameters, including proteinuria and low glomerular filtration rate, was a significant risk factor for end-stage renal disease. In human tubular epithelial HK-2 cells, IgG fractions containing anti-EPOR antibodies upregulated the expression of monocyte chemoattractant protein-1 mRNA under a high concentration of glucose. CONCLUSION: Anti-EPOR antibodies might be involved in the progression of renal lesions and in the impaired erythropoiesis in type 2 diabetic patients with CKD. Furthermore, the presence of anti-EPOR antibodies may be an additional predictor for end-stage renal disease in type 2 diabetes. Elsevier 2017-09-08 /pmc/articles/PMC5762966/ /pubmed/29340323 http://dx.doi.org/10.1016/j.ekir.2017.08.017 Text en © 2017 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Research
Hara, Akinori
Furuichi, Kengo
Koshino, Akihiko
Yasuda, Haruka
Tran, Trang Thi Thu
Iwata, Yasunori
Sakai, Norihiko
Shimizu, Miho
Kaneko, Shuichi
Nakamura, Hiroyuki
Wada, Takashi
Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD
title Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD
title_full Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD
title_fullStr Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD
title_full_unstemmed Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD
title_short Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD
title_sort clinical and pathological significance of autoantibodies to erythropoietin receptor in type 2 diabetic patients with ckd
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762966/
https://www.ncbi.nlm.nih.gov/pubmed/29340323
http://dx.doi.org/10.1016/j.ekir.2017.08.017
work_keys_str_mv AT haraakinori clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd
AT furuichikengo clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd
AT koshinoakihiko clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd
AT yasudaharuka clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd
AT trantrangthithu clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd
AT iwatayasunori clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd
AT sakainorihiko clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd
AT shimizumiho clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd
AT kanekoshuichi clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd
AT nakamurahiroyuki clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd
AT wadatakashi clinicalandpathologicalsignificanceofautoantibodiestoerythropoietinreceptorintype2diabeticpatientswithckd